In 2018, a more selective “second-generation” FLT3 inhibitor, Gilteritinib, with fewer side-effects received FDA approval for relapsed or refractory FLT3-ITD or FLT3-TKD mutations-positive AML (14) based on the results of ADMIRAL (NCT02421939) and CHRYSALIS (NCT02014558) clinical trials, both of which demonstrated significantly improved outcomes in the Gilteritinib group (15, 16). Here, FLT3 is linked to acute myeloid leukemia.